← Back
Oncology

Volrustomig (MEDI5752)

AstraZeneca

PD-1 × CTLA-4 bispecific. KEYVIBE Phase 3 trials in 1L NSCLC ongoing.

NSCLCSolid tumors

Linked Studies

NCT05327803PrimaryTERMINATEDPHASE2, PHASE3

Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease

MAC Lung DiseaseTreatment Refractory MAC Lung DiseaseUpdated May 2025
Loading comments…

Also Known As

Development codes

MEDI5752

Other names

volrustomig
Search all trials →Request coverage update